ARTICLE | Company News
Alnylam, Ascletis deal
July 16, 2012 7:00 AM UTC
Ascletis received exclusive rights in China to develop and commercialize Alnylam's RNAi therapeutic ALN-VSP, which completed a Phase I trial for liver cancer. ALN-VSP is a lipid nanoparticle formulat...